Background: Angiotensin converting enzyme inhibitor (ACEi) therapy delays the onset of renal failure in diabetic nephropathy and inhibits or delays the onset of proteinuria in several animal models. Materials and Methods: We examined this question using a transgenic model of chronic glomerulosclerosis caused by an excess production of growth hormone (GH) in which there is progressive glomerular scarring leading to uremia. In addition, since GH mice do not have systemic hypertension or an elevated glomerular filtration rate, we could address the question of whether ACEi or angiotensin II receptor antagonists (AII RA) had an effect on the development of glomerulosclerosis under these conditions. Since excess ma-
INTRODUCTION
Angiotensin converting enzyme inhibitor (ACEi) therapy delays the onset of end-stage renal failure in patients with diabetic nephropathy (1) and prevents or attenuates the development of proteinuria and renal lesions in rats with 5/6 ade on glomerulosclerosis induced by excess growth factors. Therefore, we examined mice transgenic for bovine growth hormone (GH), since the molecular basis of the glomerular lesion had been studied (9) . In this model the renal lesions lead to death in uremia and the animals are not hypertensive. Another reason for selecting this model is that GH has been shown to be a requirement for the development of glomerulosclerosis in both mice and rats (10) . Finally, the GH effect is not mediated through excess body growth, since mice transgenic for a mutant GH are of normal size but develop glomerulosclerosis (11) . The glomerular lesions in GH mice are characterized by activation of several genes coding for extracellular matrix (ECM) components (12, 13) . These changes could be mediated by a direct effect of AngII on glomerular cells, since exposure of mesangial cells to AngIl in vitro results in increased collagen synthesis (14, 15) . Since most patients have established renal disease when they come to medical attention, we studied mice treated with ACEi or AngII RA after the onset of glomerulosclerosis. Since glomerulosclerosis may result from an imbalance between matrix synthesis and degradation, we explored the effect of RAS blockade on both processes. Glomerular a l type I collagen, al type IV collagen, and a-smooth muscle cell (SMC) actin mRNAs were increased in treated GH mice. Type I collagen deposition in the mesangium was increased and 105 kD complex collagenase activity was decreased. Thus, there were changes in both the synthesis and degradation of ECM components, resulting in a net increase in glomerulosclerosis. 20 mg/kg/day, GH = 7). Both were given daily in drinking water. Control, age-matched GH mice (GH-Ctrl, n = 12) drank regular water. Additional controls consisted of non-transgenic age-matched normal SJL/C57B1 Fl mice treated with 150 mg/kg/day of captopril (WT-ACEi, n = 5) or regular water (WT-Ctrl, n = 8). Transgenic animals were identified by PCR analysis performed on detergent-extracted material from tail biopsies, using specific primers for bovine growth hormone cDNA that did not cross-react with the mouse sequence (Table 1) . Serum Creatinine, Urine Albumin, and Creatinine Albumin and creatinine were measured in spot urine samples. Albumin was determined by a modified enzyme-linked immunoabsorbent assay, as previously described (9) . Creatinine concentration was measured by a colorimetric method (Stanbio Lab, San Antonio, TX, U.S.A.).
MATERIALS AND METHODS

Blood Pressure and Glomerular Filtration Measurement
Mice were anesthetized with Inactin (Byk, Gulden Konstanz, Germany; 200 mg/kg BW, i.p.) for measurements of kidney function, as previously described in rats (16) . Briefly, following tracheotomy, in-dwelling polyethylene catheters (PE-10, Clay Adams, Parsippany, NJ, U.S.A.) were placed into the left jugular vein for infusion of plasma, inulin, and para-aminohippurate (PAH), and the left carotid artery was cannulated to monitor mean systemic arterial pressure (MAP). After priming doses of 0.2 ml of plasma and 0.2 ml of the inulin/PAH solution (3.6% v/v and 0.4% v/v, respectively), maintenance infusions were continued at 0.5 ml/hr for both plasma and inulin/PAH to maintain euvolemia. MAP was measured directly with a pressure transducer system as previously described (2) . The bladder was cannulated with PE-50, and after steadystate urine flow was present, two consecutive timed collections of urine samples were obtained through bladder cannulations for determination of urine flow rate and inulin and PAH concentrations. Arterial blood was collected into capillary tubes for determination of plasma inulin and PAH concentrations at the midpoint of urine collection. Glomerular filtration rate and renal plasma flow were then estimated by inulin and PAH clearance, respectively. Inulin concentrations in plasma and urine were determined by the macroanthrone method (17) . PAH (19) . Immunostaining was performed using an immunoperoxidase Vectastain kit (Vector Laboratories Inc., Burlingame, CA, U.S.A.). Negative controls, included in each experiment, consisted of replacement of the primary antibody by preimmune rabbit serum or by an equivalent concentration of nonimmune rabbit IgG. The specificity of TGF-,B isoforms staining was assessed by demonstrating complete blocking in the presence of a 20-fold molar excess of the immunizing peptide.
Autoradiography and Morphometry
Autoradiography was performed as previously described (20) . Body weight, 1 ,uCi/gm, of [3H]-thymidine in 200 ,ul of saline was given intraperitoneally and animals were sacrificed 16-18 hr later. Kidney sections were deparaffinized, coated with Kodak NTB-3 emulsion (International Biotechnology Inc., New Haven, CT, U.S.A.), and exposed for 3 weeks at 40C in the dark. The thymidine labeling index (TLI) was expressed as the percentage of labeled cells found by examining 50 glomerular profiles/animal. The mean glomerular cross-sectional area was measured with a computer-assisted planimeter in 100 successive glomeruli/mouse. The mean glomerular volume was calculated from the harmonic mean of the glomerular equatorial area, using the method of De Hoff and Rhines for mean size of particles of similar shape (21) .
Isolation of Glomeruli and Reverse Transcription
Glomeruli were isolated by microdissection in the presence of RNase inhibitors as previously described (22) . Briefly, after sacrificing the mouse by decapitation, the lower pole was isolated and snap frozen on dry ice for zymography GFR and Blood Pressure Direct measurement of intra-arterial blood pressure revealed no significant differences between WT-Ctrl mice (119 ± 5 mm Hg, n = 5), GH-Ctrl mice (99 19 mm Hg, n = 2), and GH-ACEi mice (89 9 mm Hg, n = 3) in 12 week animals (Fig. 1) . The inulin clearance in GH-Ctrl mice (0.43 ± 0.10 ml/min, n = 3) did not differ from WT-Ctrl (0.52 ± 0.14 ml/min, n = 4), nor did the PAH clearance (GH-ctrl = 1.33 0.55 ml/min, n = 4; versus WT-Ctrl = 1.42 0.16 ml/min, n = 3). However, there was an 85% reduction in GFR in GH-ACEi mice (0.06 ± 0.03 ml/min, n = 4). PAH clearance, which could be measured in only one GH-ACEi animal, was reduced (0.15 ml/min).
Glomerulosclerosis, Vascular Lesions
There was no apparent difference in the severity of the light microscopic glomerular lesions in GH-ACEi, GH-AII RA, or GH-Ctrl mice (Fig. 2) . All treated mice developed juxtaglomerular apparatus. (JGA) hypertrophy and conspicuous arteriolar changes directly adjacent to the JGA, consisting of intimal and medial hypercellularity, which considerably narrowed the lumen of both afferent and efferent arterioles (Fig. 2 ). There were no thrombotic or necrotic glomerular lesions, even in the vicinity of the arteriolar lesions. To determine whether the vascular lesions were related to the presence of high levels of GH in transgenic mice, five normal littermate mice were treated with ACEi, at the same dose, for 6 weeks. While vascular changes with the same distribution as in GH-ACEi and GH-AngII RA mice were observed, they appeared less severe (Fig. 3) .
To determine if the lesions were due to the high drug dosage used in this study, five 6-weekold GH mice were given 1/1Oth the dose (15 mg/kg/day) for 6 weeks. The vascular lesions were identical to animals given the higher ACEi doses (data not shown).
Type I collagen was increased in the glomeruli of GH-ACEi and GH-AngII RA mice, compared with GH-Ctrl by immunofluorescence microscopy (Figs. 4A and 4B ). The increased deposition was concentrated in the zone close to the vascular pole of the glomerular tuft. The affected arterioles also contained large amounts of type I collagen in their walls (Fig. 4B) , whereas normal afferent and efferent arterioles resembled controls.
The intensity and distribution of glomerular type IV treatment appears to prevent the development or progression of glomerular lesions in some animal models (3, 4, (24) (25) (26) (27) . In addition, ACEi therapy prolongs the time to doubling of the serum creatinine in type I diabetics with advanced nephropathy (1). ACEi has been postulated to have renoprotective effects that are separate from its vasopressor actions on the glomerulus, especially at high (10-fold) doses (27) . At this high level the local glomerular RAS may be inhibited, preventing mesangial cell activation and glomerular hypertrophy (28) . The current study was undertaken to examine the potential role of AII in a model of growth factor-induced glomerulosclerosis. Six-week-old GH mice were given ACEi or AngIl RA for a period of 6 weeks. At 12 weeks, untreated GH mice had a normal glomerular filtration rate and blood pressure, but had glomerulosclerosis with elevated levels of glomerular types I and IV collagen mRNAs, as well as an increased glomerular cell turnover rate. While systemic blood pressure in ACEi GH mice did not differ from either normal littermates or untreated GH mice, their GFR was reduced by 85%. Neither treatment affected body weight increase, serum creatinine, urine albumin/creatinine ratio, or glomerular volume.
The glomerular lesions in ACEi or AngII RAtreated GH mice were not attenuated and differed from one another. In both groups there was an increase in the glomerular labeling index, the deposition of type I collagen by immunofluorescence microscopy, and the levels of type I collagen mRNA. There was also decreased 105 kD and 75 kD metalloproteinase activity by zy- The role of AngIl in renal diseases has been recently reviewed (30) . AngIl infusion in rats resulted in mesangial cell proliferation and increased mesangial aSMC actin expression, a potential marker of mesangial activation (31) . The reduction of glomerular lesions in rats treated with ACEi, and more recently with AngII RA, supports the postulate that AnglI may play an important role in the development of glomerular injury in some animal models (3) (4) (5) (34, 35) . Therefore, we examined TGF-j31, ,32, and /33 immunostaining. There were no changes in the pattern of TGF-f31, /2, or /3 isoform staining, making it unlikely that increased TGF-,B was the cause of the vascular lesions. Other growth factor(s) could have been synthesized locally in response to ACE or AnglI ATI receptor blockade. Since AngIl induces hypertrophy and hyperplasia in vascular smooth muscle cells (36) , it is a potential candidate.
In conclusion, angiotensin II appears to have a direct effect on both glomerular and arteriolar cells in vivo. Additionally, GH mice represent a disease model in which blockade of the RAS has deleterious effects. It may be important to study the molecular basis of AII effect(s) on other forms of glomerulosclerosis, especially those in which AII does not appear to play a major role.
